AAPL   367.57 (+0.95%)
MSFT   207.77 (+1.50%)
FB   236.20 (-0.57%)
GOOGL   1,477.57 (+2.47%)
AMZN   2,894.21 (+0.54%)
NVDA   385.67 (+1.17%)
CGC   16.37 (-0.61%)
MU   50.28 (+1.17%)
GE   6.86 (+1.78%)
TSLA   1,212.57 (+8.30%)
T   30.27 (+1.20%)
F   6.10 (+1.84%)
DIS   113.32 (+0.27%)
BAC   23.39 (+0.56%)
BA   182.87 (+1.41%)
AAPL   367.57 (+0.95%)
MSFT   207.77 (+1.50%)
FB   236.20 (-0.57%)
GOOGL   1,477.57 (+2.47%)
AMZN   2,894.21 (+0.54%)
NVDA   385.67 (+1.17%)
CGC   16.37 (-0.61%)
MU   50.28 (+1.17%)
GE   6.86 (+1.78%)
TSLA   1,212.57 (+8.30%)
T   30.27 (+1.20%)
F   6.10 (+1.84%)
DIS   113.32 (+0.27%)
BAC   23.39 (+0.56%)
BA   182.87 (+1.41%)
AAPL   367.57 (+0.95%)
MSFT   207.77 (+1.50%)
FB   236.20 (-0.57%)
GOOGL   1,477.57 (+2.47%)
AMZN   2,894.21 (+0.54%)
NVDA   385.67 (+1.17%)
CGC   16.37 (-0.61%)
MU   50.28 (+1.17%)
GE   6.86 (+1.78%)
TSLA   1,212.57 (+8.30%)
T   30.27 (+1.20%)
F   6.10 (+1.84%)
DIS   113.32 (+0.27%)
BAC   23.39 (+0.56%)
BA   182.87 (+1.41%)
AAPL   367.57 (+0.95%)
MSFT   207.77 (+1.50%)
FB   236.20 (-0.57%)
GOOGL   1,477.57 (+2.47%)
AMZN   2,894.21 (+0.54%)
NVDA   385.67 (+1.17%)
CGC   16.37 (-0.61%)
MU   50.28 (+1.17%)
GE   6.86 (+1.78%)
TSLA   1,212.57 (+8.30%)
T   30.27 (+1.20%)
F   6.10 (+1.84%)
DIS   113.32 (+0.27%)
BAC   23.39 (+0.56%)
BA   182.87 (+1.41%)
Log in

NYSE:GSKGlaxoSmithKline News Headlines

$41.14
+0.29 (+0.71 %)
(As of 07/2/2020 12:43 PM ET)
Add
Compare
Today's Range
$40.95
Now: $41.15
$41.28
50-Day Range
$40.21
MA: $41.28
$42.74
52-Week Range
$31.43
Now: $41.15
$48.25
Volume1.71 million shs
Average Volume3.00 million shs
Market Capitalization$103.21 billion
P/E Ratio15.02
Dividend Yield4.56%
Beta0.7

Headlines

GlaxoSmithKline (NYSE GSK) News Headlines

Source:
DateHeadline
GSK says within weeks of resubmitting HIV injection CabenuvaGSK says within weeks of resubmitting HIV injection Cabenuva
finance.yahoo.com - July 2 at 10:51 AM
J&J (JNJ) Discontinues Phase III Study of Stelara for LupusJ&J (JNJ) Discontinues Phase III Study of Stelara for Lupus
finance.yahoo.com - June 29 at 1:09 PM
GlaxoSmithKline (GSK) Stock Moves -1.39%: What You Should Know - Yahoo FinanceGlaxoSmithKline (GSK) Stock Moves -1.39%: What You Should Know - Yahoo Finance
finance.yahoo.com - June 26 at 10:12 PM
GlaxoSmithKline (GSK) Stock Moves -1.39%: What You Should KnowGlaxoSmithKline (GSK) Stock Moves -1.39%: What You Should Know
finance.yahoo.com - June 26 at 10:12 PM
Acquiring Biomarin Would Speed Sanofi Transition to New TherapiesAcquiring Biomarin Would Speed Sanofi Transition to New Therapies
finance.yahoo.com - June 25 at 4:05 PM
REFILE-Fulcrum Therapeutics begins trial of muscle disorder drug for COVID-19 patientsREFILE-Fulcrum Therapeutics begins trial of muscle disorder drug for COVID-19 patients
finance.yahoo.com - June 24 at 7:51 AM
GlaxoSmithKline plc (NYSE:GSK) Given Average Rating of "Hold" by AnalystsGlaxoSmithKline plc (NYSE:GSK) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - June 23 at 6:55 PM
RPT-GSK in quest to be best, not first, in race for COVID-19 vaccineRPT-GSK in quest to be best, not first, in race for COVID-19 vaccine
www.reuters.com - June 22 at 6:46 PM
US Stocks That Surged Higher This Week: $GSK $AGRX $DXCMUS Stocks That Surged Higher This Week: $GSK $AGRX $DXCM
www.marketwatch.com - June 22 at 6:46 PM
Glaxo's Partner Begins Phase I Study on Coronavirus VaccineGlaxo's Partner Begins Phase I Study on Coronavirus Vaccine
finance.yahoo.com - June 22 at 1:45 PM
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKlines Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple Myeloma - GlobeNewswireSpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKline's Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple Myeloma - GlobeNewswire
www.globenewswire.com - June 22 at 8:07 AM
GlaxoSmithKline plc (NYSE:GSK) Expected to Announce Quarterly Sales of $10.13 BillionGlaxoSmithKline plc (NYSE:GSK) Expected to Announce Quarterly Sales of $10.13 Billion
www.americanbankingnews.com - June 20 at 3:50 AM
Top Analyst Reports for AbbVie, Oracle & GlaxoSmithKlineTop Analyst Reports for AbbVie, Oracle & GlaxoSmithKline
finance.yahoo.com - June 19 at 2:39 PM
Form 6-K GLAXOSMITHKLINE PLC For: Jun 18 - StreetInsider.comForm 6-K GLAXOSMITHKLINE PLC For: Jun 18 - StreetInsider.com
www.streetinsider.com - June 18 at 1:37 PM
GlaxoSmithKline plc (NYSE:GSK) Expected to Announce Earnings of $0.60 Per ShareGlaxoSmithKline plc (NYSE:GSK) Expected to Announce Earnings of $0.60 Per Share
www.americanbankingnews.com - June 18 at 11:35 AM
GlaxoSmithKline To Raise New Funds Through Issue Of Senior Notes - MorningstarGlaxoSmithKline To Raise New Funds Through Issue Of Senior Notes - Morningstar
www.morningstar.co.uk - June 17 at 9:27 AM
GlaxoSmithKline (NYSE:GSK) Receives News Impact Rating of -3.53GlaxoSmithKline (NYSE:GSK) Receives News Impact Rating of -3.53
www.americanbankingnews.com - June 16 at 5:48 PM
Glaxo (GSK) HIV Drug Tivicay Gets FDA Approval for Toddlers - Yahoo FinanceGlaxo (GSK) HIV Drug Tivicay Gets FDA Approval for Toddlers - Yahoo Finance
finance.yahoo.com - June 15 at 2:19 PM
GlaxoSmithKline Sees Unusually High Options Volume (NYSE:GSK)GlaxoSmithKline Sees Unusually High Options Volume (NYSE:GSK)
www.americanbankingnews.com - June 15 at 12:46 PM
Glaxosmithkline - London South EastGlaxosmithkline - London South East
www.lse.co.uk - June 15 at 9:18 AM
Global DNA Vaccine Market Outlook to 2022 - Featuring Bharat Biotech, GlaxoSmithKline & Green Cross Among Others - ResearchAndMarkets.com - Yahoo FinanceGlobal DNA Vaccine Market Outlook to 2022 - Featuring Bharat Biotech, GlaxoSmithKline & Green Cross Among Others - ResearchAndMarkets.com - Yahoo Finance
finance.yahoo.com - June 15 at 9:18 AM
GSK gets FDA approval for HIV drug for childrenGSK gets FDA approval for HIV drug for children
finance.yahoo.com - June 15 at 9:18 AM
Is GlaxoSmithKline plc (GSK) Going to Burn These Hedge Funds? - Yahoo FinanceIs GlaxoSmithKline plc (GSK) Going to Burn These Hedge Funds? - Yahoo Finance
finance.yahoo.com - June 8 at 11:51 PM
Is GlaxoSmithKline plc (GSK) Going to Burn These Hedge Funds?Is GlaxoSmithKline plc (GSK) Going to Burn These Hedge Funds?
finance.yahoo.com - June 8 at 6:50 PM
Drugmakers Target Coronavirus Vaccine in 2020: 4 Stocks in FocusDrugmakers Target Coronavirus Vaccine in 2020: 4 Stocks in Focus
finance.yahoo.com - June 8 at 8:48 AM
GlaxoSmithKline Stock Should Get Boost From Promising Drug Pipeline - BarronsGlaxoSmithKline Stock Should Get Boost From Promising Drug Pipeline - Barron's
www.barrons.com - June 4 at 8:39 AM
GlaxoSmithKline’s Promising Drug Pipeline Should Drive the Stock HigherGlaxoSmithKline’s Promising Drug Pipeline Should Drive the Stock Higher
finance.yahoo.com - June 4 at 8:39 AM
Glaxo Plans to Make 1B Doses of Coronavirus Vaccine AdjuvantGlaxo Plans to Make 1B Doses of Coronavirus Vaccine Adjuvant
finance.yahoo.com - May 29 at 1:16 PM
Is GlaxoSmithKline plcs (LON:GSK) High P/E Ratio A Problem For Investors?Is GlaxoSmithKline plc's (LON:GSK) High P/E Ratio A Problem For Investors?
finance.yahoo.com - May 29 at 8:15 AM
GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know - NasdaqGlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know - Nasdaq
www.nasdaq.com - May 28 at 7:27 PM
GlaxoSmithKline (GSK) Gains As Market Dips: What You Should KnowGlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
finance.yahoo.com - May 28 at 7:27 PM
GlaxoSmithKline Teams Up With Mammoth Biosciences on a CRISPR-Based COVID-19 TestGlaxoSmithKline Teams Up With Mammoth Biosciences on a CRISPR-Based COVID-19 Test
www.nasdaq.com - May 23 at 6:30 PM
S.Koreas Samsung Biologics signs $231 mln supply deal with GSKS.Korea's Samsung Biologics signs $231 mln supply deal with GSK
finance.yahoo.com - May 22 at 9:11 AM
S.Korea's Samsung Biologics signs $231 mln supply deal with GSKS.Korea's Samsung Biologics signs $231 mln supply deal with GSK
finance.yahoo.com - May 21 at 11:43 PM
South Korea's Samsung Biologics signs $231 million supply deal with GSKSouth Korea's Samsung Biologics signs $231 million supply deal with GSK
finance.yahoo.com - May 21 at 11:43 PM
Glaxosmithkline share price hits a one-year highGlaxosmithkline share price hits a one-year high
uk.finance.yahoo.com - May 21 at 8:41 AM
The Glaxosmithkline share price – where next?The Glaxosmithkline share price – where next?
uk.finance.yahoo.com - May 21 at 8:41 AM
Stocks Trading Above Their Pivot Point: $GSK $C $TOTStocks Trading Above Their Pivot Point: $GSK $C $TOT
www.marketwatch.com - May 21 at 8:41 AM
Gilead, Galapagos Announce Positive Data on Inflammatory DrugGilead, Galapagos Announce Positive Data on Inflammatory Drug
finance.yahoo.com - May 21 at 8:41 AM
GSK ties up with gene editing start-up Mammoth for COVID-19 testGSK ties up with gene editing start-up Mammoth for COVID-19 test
finance.yahoo.com - May 20 at 12:39 PM
GSK fights to bar lawyer-funded Zofran birth-defect study from trialGSK fights to bar lawyer-funded Zofran birth-defect study from trial
www.reuters.com - May 20 at 7:35 AM
GlaxoSmithKline, Pfizer, and Shionogi's HIV Prevention Candidate Outperforms Gilead's TruvadaGlaxoSmithKline, Pfizer, and Shionogi's HIV Prevention Candidate Outperforms Gilead's Truvada
finance.yahoo.com - May 19 at 4:03 PM
BRIEF-Glaxosmithkline Pharmaceuticals March Qtr Profit Falls - ReutersBRIEF-Glaxosmithkline Pharmaceuticals March Qtr Profit Falls - Reuters
www.reuters.com - May 18 at 1:32 PM
Form 6-K GLAXOSMITHKLINE PLC For: May 18 - StreetInsider.comForm 6-K GLAXOSMITHKLINE PLC For: May 18 - StreetInsider.com
www.streetinsider.com - May 18 at 8:32 AM
Glaxo-held firm ends HIV study early as injectable shows higher efficacy than daily pillGlaxo-held firm ends HIV study early as injectable shows higher efficacy than daily pill
finance.yahoo.com - May 18 at 8:32 AM
GSK's long-acting injection beats Truvada in HIV prevention trialGSK's long-acting injection beats Truvada in HIV prevention trial
finance.yahoo.com - May 18 at 8:32 AM
Identification and Characterization of a Potential Therapeutic COVID-19 Antibody by Vir Biotechnology Published in NatureIdentification and Characterization of a Potential Therapeutic COVID-19 Antibody by Vir Biotechnology Published in Nature
finance.yahoo.com - May 18 at 8:32 AM
Trump presses for coronavirus vaccine by end of yearTrump presses for coronavirus vaccine by end of year
finance.yahoo.com - May 15 at 2:44 PM
Why quality and momentum matters for Glaxosmithkline Pharmaceuticals (NSI:GLAXO) - Yahoo Finance UKWhy quality and momentum matters for Glaxosmithkline Pharmaceuticals (NSI:GLAXO) - Yahoo Finance UK
uk.finance.yahoo.com - May 14 at 7:36 AM
WHO official’s grim outlook on COVID-19: ‘This virus may never go away’WHO official’s grim outlook on COVID-19: ‘This virus may never go away’
finance.yahoo.com - May 14 at 2:36 AM
This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.